Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00623974 · ClinicalTrials.gov registry record · Phase 2
Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00623974: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00623974 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00623974, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
Primary Objective: -To identify the optimal dose of a seven-day course of twice-daily teriparatide as compared to standard therapy for hypocalcemia in patients after total thyroidectomy and/or extensive neck dissections (pharyngectomy, laryngectomy,unilateral, bilateral / central neck, mediastinal lymph node neck dissections), with which serum calcium will be raised to corrected serum calcium levels of 8-10.5mg/dL and maintained within this range until the end of the treatment course.
Interventions
- DRUG Calcitriol
- DRUG Calcium
- DRUG Teriparatide (Forteo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00623974
The ClinicalTrials.gov registry entry for NCT00623974 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Calcitriol is the first listed.
NCT00623974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00623974 about?
NCT00623974 is a clinical study titled "Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia". Primary Objective: -To identify the optimal dose of a seven-day course of twice-daily teriparatide as compared to standard therapy for hypocalcemia in patients after total thyroidectomy and/or extensive neck dissections (pharyngectomy, laryngectomy,unilateral, bilateral / central neck, mediastinal ...
What is the current status of trial NCT00623974?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2008-05. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00623974?
The interventions under investigation include: Calcitriol (DRUG), Calcium (DRUG), Teriparatide (Forteo) (DRUG).
Who is sponsoring clinical trial NCT00623974?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.